Therapy of endocrine disease: Treatment of malignant pheochromocytoma and paraganglioma

European Journal of Endocrinology

Volumn 171, Issue 3, 2014, Pages R111-R122

  Baudin, Eric ^a   Habra, Mouhammed Amir ^b   Deschamps, Frederic ^a   Cote, Gilbert ^b   Dumont, Frederic ^a   Cabanillas, Maria ^b   Arfi Roufe, J ^a   Berdelou, A ^a   Moon, Bryan ^b   Ghuzlan, Abir Al ^a   Patel, Shreyaskumar ^b   Leboulleux, Sophie ^a   Jimenez, Camilo ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA METHYLDOPAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOPAMINE; DOXORUBICIN; IMATINIB; MITOZOLOMIDE; NORADRENALIN; NORMETADRENALIN; PHENOXYBENZAMINE; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; GASTROINTESTINAL HEMORRHAGE; HORMONE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; MOLECULARLY TARGETED THERAPY; MORBIDITY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PARAGANGLIOMA; PATIENT REFERRAL; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; TUMOR GROWTH; ADRENAL TUMOR; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); ENDOCRINE DISEASE; METHODOLOGY; TREATMENT OUTCOME;

ADRENAL GLAND NEOPLASMS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENDOCRINE SYSTEM DISEASES; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; TREATMENT OUTCOME;

EID: 84907220377     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0113     Document Type: Review

References (59)

1. Baudin E. Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nature Clinical Practice. Endocrinology & Metabolism 2007 3 228-239. (doi:10.1038/ncpendmet0425)
2. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. Journal of Clinical Endocrinology and Metabolism 2011 96 717-725. (doi:10.1210/jc.2010-1946)
3. Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, Pacak K & Lenders JW. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocrine-Related Cancer 2008 15 1127-1133. (doi:10.1677/ERC-08-0049)
4. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A & Lenders JW. Plasma metanephrines are markers of pheochromocytoma produced by catechol- O-methyltransferase within tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 2175-2185. (doi:10.1210/jcem.83.6.4870)
5. van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den Meiracker AH, Stijnen TH & Boomsma F. The value of plasma markers for the clinical behaviour of phaeochromocytomas. European Journal of Endocrinology 2002 147 85-94. (doi:10.1530/eje.0.1470085)
6. Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, Brouwers FM & Pacak K. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clinical Chemistry 2005 51 735-744. (doi:10.1373/clinchem.2004.045484)
7. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R & Lamberts SW. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the a-subunit of glycoprotein hormones. Journal of Clinical Endocrinology and Metabolism 1997 82 2622-2628.
8. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. Journal of Clinical Endocrinology and Metabolism 2007 92 3822-3828. (doi:10.1210/jc.2007-0709)
9. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A et al. Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology 2005 23 8812-8818. (doi:10.1200/JCO.2005.03.1484)
10. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF & Jeunemaitre X. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research 2003 63 5615-5621.
11. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW & Pacak K. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. Journal of Clinical Oncology 2007 25 2262-2269. (doi:10.1200/JCO.2006.09.6297)
12. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 2003 88 4083-4087. (doi:10.1210/jc.2003-030235)
13. Muros MA, Llamas-Elvira JM, Rodriguez A, Ramirez A, Gomez M, Arraez MA, Valencia E & Vilchez R. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nuclear Medicine Communications 1998 19 735-742. (doi:10.1097/00006231-199808000-00003)
14. Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA & Jimenez C. Bone metastases and skeletalrelated events in patients with malignant pheochromocytoma and sympathetic paraganglioma. Journal of Clinical Endocrinology and Metabolism 2013 98 1492-1497. (doi:10.1210/jc.2012-4231)
15. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M & Baudin E. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Current Oncology Reports 2013 15 356-371. (doi:10.1007/s11912-013-0320-x)
16. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Journal of Clinical Oncology 2005 23 70-78. (doi:10.1200/JCO.2005.01.013)
17. Leboulleux S, Dromain C, Vataire AL, Malka D, Aupérin A, Lumbroso J, Duvillard P, Elias D, Hartl DM, De Baere T et al. Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. Journal of Clinical Endocrinology and Metabolism 2008 93 3021-3028. (doi:10.1210/jc.2008-0459)
18. Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud- Salinas C, de la Fouchardiere C, Libe R, Do Cao C, Niccoli P et al. Oneyear progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. Journal of Clinical Endocrinology and Metabolism 2013 98 4006-4012. (doi:10.1210/jc.2013-1907)
19. Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S & Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012 118 2804-2812. (doi:10.1002/cncr.26577)
20. Vanharanta S, Buchta M, McWhinney SR, Virta SK, Peczkowska M, Morrison CD, Lehtonen R, Januszewicz A, Jarvinen H, Juhola M et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. American Journal of Human Genetics 2004 74 153-159. (doi:10.1086/381054)
21. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. Journal of Clinical Endocrinology and Metabolism 2012 97 4040-4050. (doi:10.1210/jc.2012-2356)
22. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP & Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. Journal of Endocrinological Investigation 1997 20 648-658. (doi:10.1007/BF03348026)
23. Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E& Jimenez C. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Hormone and Metabolic Research 2012 44 390-399. (doi:10.1055/s-0031-1299707)
24. Adjalle R, Plouin PF, Pacak K & Lehnert H. Treatment of malignant pheochromocytoma. Hormone and Metabolic Research 2009 41 687-696. (doi:10.1055/s-0029-1231025)
25. Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Annals of the New York Academy of Sciences 2006 1073 405-416. (doi:10.1196/annals.1353.044)
26. Brogden RN, Heel RC, Speight TM & Avery GS. α-Methyl-p-tyrosine: a review of its pharmacology and clinical use. Drugs 1981 21 81-89. (doi:10.2165/00003495-198121020-00001)
27. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. Journal of Clinical Endocrinology and Metabolism 2013 98 31-42. (doi:10.1210/jc. 2012-2909)
28. Hashimoto Y, Motoyoshi S, Maruyama H, Sakakida M, Yano T, Yamaguchi K, Goto K, Sugihara S, Takano S, Kambara T et al. The treatment of pheochromocytoma associated with pseudo-obstruction and perforation of the colon, hepatic failure, and DIC. Japanese Journal ofMedicine 1990 29 341-346. (doi:10.2169/internalmedicine1962.29.341)
29. Tack J & Muller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clinical Gastroenterology andHepatology 20097502-508 quiz 496. (doi:10.1016/j.cgh.2008.12.006)
30. Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J et al. Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocrine-Related Cancer 2009 16 281-290. (doi:10.1677/ERC-08-0190)
31. 131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. Journal of Clinical Oncology 2009 27 4162-4168. (doi:10.1200/JCO.2008.21.3496)
32. Forrer F, Riedweg I, Maecke HR & Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 52 334-340.
33. Coleman RE, Stubbs JB, Barrett JA, de la Guardia M, Lafrance N & Babich JW. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biotherapy & Radiopharmaceuticals 2009 24 469-475. (doi:10.1089/cbr.2008.0584)
34. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H & Plouin PF. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Hormone and Metabolic Research 2012 44 385-389. (doi:10.1055/s-0031- 1301339)
35. Berruti A, Baudin E, GelderblomH, Haak HR, Porpiglia F, FassnachtM& Pentheroudakis G. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012 23 (Suppl 7) vii131-vii138. (doi:10.1093/annonc/mds231)
36. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, Tyler DS & Olson JA Jr. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003 134 956-962 discussion 962-963. (doi:10.1016/S0039-6060(03)00426-4)
37. 131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 1991 72 455-461. (doi:10.1210/jcem-72-2-455)
38. Gedik GK, Hoefnagel CA, Bais E & Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 725-733. (doi:10.1007/s00259-007-0652-6)
39. Wakabayashi H, Taki J, Inaki A, Nakamura A, Kayano D, Fukuoka M, Matsuo S, Nakajima K & Kinuya S. Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Annals of Nuclear Medicine 2013 27 839-846. (doi:10.1007/s12149-013-0755-z)
40. 177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. Journal of Nuclear Medicine 2006 47 1599-1606.
41. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, Niccoli P, Leboulleux S, Amar L, Borson-Chazot F et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. Journal of Clinical Endocrinology and Metabolism 2013; 98: E162-E173. (doi:10.1210/jc.2012-2975)
42. Mundschenk J, Unger N, Schulz S, Hollt V, Steinke R & Lehnert H. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. Journal of Clinical Endocrinology and Metabolism 2003 88 5150-5157. (doi:10.1210/jc.2003-030262)
43. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R& Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Annals of Internal Medicine 1988 109 267-273. (doi:10.7326/0003- 4819-109-4-267)
44. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K & Fojo T. Treatment of malignant pheochromocytoma/ paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of patients Cancer 2008 113 2020-2028. (doi:10.1002/cncr.23812)
45. Patel SR, Winchester DJ & Benjamin RS. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 1995 76 1476-1480. (doi:10.1002/1097-0142(19951015)76:8!1476::AIDCNCR2820760827O3.0. CO;2-9)
46. Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A & Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Hormones & Cancer 2013 4 103-110. (doi:10.1007/s12672-013-0133-2)
47. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B & Salazar R. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012 95 157-176. (doi:10.1159/000335597)
48. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnet C et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pechromocytoma or paragangliom. International Journal of Cancer, 2014. In press. (doi:10.1002/ijc.28913)
49. Druce MR, Kaltsas GA, FraenkelM, Gross DJ & Grossman AB. Novel and evolving therapies in the treatment ofmalignant phaeochromocytoma: experience with themTOR inhibitor everolimus (RAD001). Hormone and Metabolic Research 2009 41 697-702. (doi:10.1055/s-0029-1220687)
50. Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW & Bang YJ. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 2012 118 6162-6170. (doi:10.1002/cncr. 27675)
51. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer 2006 13 535-540. (doi:10.1677/erc.1.01124)
52. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A & Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology 2006 24 401-406. (doi:10.1200/JCO.2005. 03.6046)
53. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. Journal of Clinical Endocrinology and Metabolism 2009 94 386-391. (doi:10.1210/jc.2008-1972)
54. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M & Knox JJ. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 2009 94 5-9. (doi:10.1210/jc.2008-1836)
55. Favier J, Igaz P, Burnichon N, Amar L, Libe R, Badoual C, Tissier F, Bertherat J, Plouin PF, Jeunemaitre X et al. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocrine Pathology 2012 23 34-42. (doi:10.1007/s12022-011-9189-0)
56. Letouze E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, Janin M, Menara M, Nguyen AT, Benit P et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013 23 739-752. (doi:10.1016/j.ccr.2013.04.018)
57. Loriot C, Burnichon N, Gadessaud N, Vescovo L, Amar L, Libe R, Bertherat J, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. Journal of Clinical Endocrinology and Metabolism 2012; 97: E954-E962. (doi:10.1210/jc.2011-3437)
58. Burnichon N, Buffet A, Parfait B, Letouze E, Laurendeau I, Loriot C, Pasmant E, Abermil N, Valeyrie-Allanore L, Bertherat J et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics 2012 21 5397-5405. (doi:10.1093/hmg/dds374)
59. Crona J, Delgado Verdugo A, Maharjan R, Stalberg P, Granberg D, Hellman P & Bjorklund P. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. Journal of Clinical Endocrinology and Metabolism 2013 98 E1266-E1271. (doi:10.1210/jc.2012-4257)